ERBB2 and breast carcinoma: Most HER2-positive breast cancer patients receive NAT that includes trastuzumab and pertuzumab, monoclonal antibodies targeting the extracellular and dimerization domain of HER2, respectively, a well-established therapeutic strategy that has positively affected prognosis [27,28,29].